Drug details

Ukoniq (umbralisib tablets)

type of How Do Antineoplastic CDK Inhibitors Work?

Ukoniq (umbralisib) is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.

The following drugs are related to Ukoniq, either as a replacement or used together:

• Calquence (acalabrutinib capsules)
• Adcetris (brentuximab vedotin)
• Aliqopa (copanlisib for injection, for intravenous use)
• Arranon (nelarabine)
• Beleodaq (belinostat for injection for intravenous use)
• Bendeka (bendamustine hydrochloride injection)
• Brukinsa (zanubrutinib capsules)
• Ontak (denileukin diftitox)
• Folotyn (pralatrexate solution for intravenous injection)
• Gazyva (obinutuzumab injection)
• Imbruvica (ibrutinib capsules)
• Istodax (romidepsin for injection)
• Keytruda (pembrolizumab for injection)
• Kymriah (tisagenlecleucel suspension for intravenous infusion)
• Zynlonta (loncastuximab tesirine-lpyl for injection)
• Lunsumio (mosunetuzumab-axgb injection)
• Monjuvi (tafasitamab-cxix injection)
• Polivy (polatuzumab vedotin-piiq for injection)
• Tazverik (tazemetostat tablets)